GlassScriptPhysician profile
Austin Adams
NPI 1669508891
$740.47
in general payments reported to CMS, 2019-2025
14 companies · $467 in 2025
The $467 reported for 2025 was more than what 83% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.32 · 2023: $36.86 · 2024: $223 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $154.25 | 2023-2025 | Spravato |
| Cequr Corporation | $99.70 | 2024-2025 | Cequr Simplicity |
| Abbvie INC. | $87.20 | 2024-2025 | |
| Novo Nordisk INC | $87.08 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $54.10 | 2025 | Cologuard Collection Kit |
| Alkermes, INC. | $46.98 | 2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.07 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $45.11 | 2025 | |
| Astellas Pharma US INC | $27.81 | 2025 | Veozah |
| Acadia Pharmaceuticals INC | $24.73 | 2025 | Daybue |
| Seqirus USA INC | $20.12 | 2025 | Fluad, Flucelvax |
| Lilly USA, LLC | $18.63 | 2025 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $15.37 | 2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.